4.5 Interaction with other medicinal products and other forms of interaction 
 No formal assessments of pharmacokinetic interactions between TRISENOX and other therapeutic medicinal products have been conducted.  
 Medicinal products known to cause QT/QTc interval prolongation, hypokalaemia  or hypomagnesaemia  QT/QTc prolongation is expected during treatment with arsenic trioxide, and torsade de pointes and complete heart block have been reported. Patients who are receiving, or who have received, medicinal products known to cause hypokalaemia  or hypomagnesaemia, such as diuretics or amphotericin B, 7 may be at higher risk fo r torsade de pointes. Caution is advised when TRISENOX is co -administered with other medicinal products known to cause QT/QTc interval prolongation such as macrolide antibiotics, the antipsychotic thioridazine, or medicinal products known to cause hypokala emia  or hypomagnesaemia. Additional information about QT prolonging medicinal agents, is provided in section  4.4. 
 Medicinal products known to cause hepatotoxic effects  Hepatotoxic effects may occur during the treatment with arsenic trioxide, caution is ad vised when TRISENOX is co -administered with other medicinal products known to cause h epatotoxic effects (see section  4.4 and 4.8).  
 Other antileukaemic medicinal products The influence of TRISENOX on the efficacy of other antileukaemic medicinal products i s unknown.  
 
